Kodiak Sciences shares surged 150% after its wet-AMD drugs Zenkuda and tabirafusp-ted met primary endpoints in the pivotal Phase 3 DAYBREAK trial. The company plans to file Zenkuda for approval in Q4, backed by five positive Phase 3 studies.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
